-
Man United, Bayern cruise as Como make dream Champions League start
-
Russian strike on Ukraine shopping centre kills five
-
Musiala returns to help Bayern sink Bodo in Champions League
-
Man Utd outclass Sabah on Champions League return
-
Surging oil prices, higher bond yields weigh on stocks
-
Russian strike on Ukraine shopping centre kills at least six
-
Russell admits he needs luck as Antonelli focuses on the job
-
Gauff salutes Zina Garrison, 'pioneer' in Black tennis
-
Canada pledges support for Ukraine air defense as Zelensky visits
-
Carney says in touch with Trump, Canada ready for 'fair' trade deal
-
Latin America fact-check group asks Meta not to replace verification practice
-
Morocco says not involved in Ceuta migrant influx
-
Seahawks' Darnold gets good news on hip injury: coach
-
Tag Markets Names Craig Lund Chief Executive Officer
-
Evasive Alonso teases reporters on his F1 future
-
Ex-president Bush remembers 9/11 through exhibit of his art
-
What to know about Trump's $5,000 'dividend' pledge
-
F1 drivers expecting crashes, chaos at new Spanish GP circuit
-
Leclerc concedes he 'went too far' in Hamilton Monza incident
-
NGO chief sees 'hypocrisy' in Afghan women's rights calls amid aid cuts
-
Shelton, Tiafoe in spotlight as Zverev aims to build on Grand Slam success
-
Latin America could see fresh disinformation after Meta changes
-
England close in on Test series sweep against sorry Pakistan
-
UAE to invest 40 billion euros in Germany, including for data centres: Berlin
-
England dominate sorry Pakistan, close in on Test series sweep
-
2030 Winter Olympics chief Grospiron quits
-
Kung wins Vuelta time-trial as Mas retains lead
-
AI Risks to Enter 60–80% of Liability and Cyber Insurance Underwriting by 2028, ScienceSoft Predicts
-
DR Congo school fire leaves at least 14 children dead
-
Ultimate Championship as big as Olympics - and more lucrative, says Bolt
-
USA and France ease into women's Basketball World Cup semis
-
Diana's 'revenge dress' to go up for auction in New York
-
ECB lifts borrowing costs amid energy shock, opens door for more hikes
-
England dominate Pakistan, close in on Test series sweep
-
France defeat China to reach women's basketball World Cup semis
-
Russia trafficking foreigners to fight in Ukraine, Amnesty says
-
Tribal Launches Campfire, Letting Business and Technical Teams Build on Salesforce Together
-
Global Tokenized Real Estate Market to Hit up to $3 Trillion by 2030, ScienceSoft Predicts
-
Yemen's Houthis seize key city on Red Sea
-
Stocks fall as fresh oil surge fans inflation fears
-
US producer inflation tops expectations as diesel costs jump
-
August hottest month ever recorded globally as huge El Nino emerges
-
Rubio ends South America swing with Peru security talks
-
'Bragging rights' up for grabs at game-changing Ultimate Championship, says Coe
-
Defiant Iran seeks to bruise Trump ahead of midterms
-
ECB hikes borrowing costs to combat Mideast energy shock
-
France withdraws support for Infantino in FIFA presidential election
-
England turn screw in 3rd Test against Pakistan
-
Evolution Metals & Technologies Provides Initial Revenue Guidance of $400-460mm for Fiscal Year 2027
-
France will not support Infantino in FIFA election: federation chief
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
X.Brito--PC